105 related articles for article (PubMed ID: 33342803)
1. Increased breast cancer cell sensitivity to cisplatin using a novel small molecule inhibitor.
Hatzidaki E; Daikopoulou V; Apostolou P; Ntanovasilis DA; Papasotiriou I
J Cancer Res Ther; 2020; 16(6):1393-1401. PubMed ID: 33342803
[TBL] [Abstract][Full Text] [Related]
2. Multikinase inhibitor motesanib enhances the antitumor effect of cisplatin in cisplatin‑resistant human bladder cancer cells via apoptosis and the PI3K/Akt pathway.
Ho JN; Byun SS; Lee SE; Youn JI; Lee S
Oncol Rep; 2019 Apr; 41(4):2482-2490. PubMed ID: 30816494
[TBL] [Abstract][Full Text] [Related]
3. Sildenafil enhances cisplatin-induced apoptosis in human breast adenocarcinoma cells.
Hassanvand F; Mohammadi T; Ayoubzadeh N; Tavakoli A; Hassanzadeh N; Sanikhani NS; Azimi AI; Mirzaei HR; Khodamoradi M; Goudarzi KA; Pourghadamyari H; Zaimy MA
J Cancer Res Ther; 2020; 16(6):1412-1418. PubMed ID: 33342806
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of p90 ribosomal S6 kinase potentiates cisplatin activity in A549 human lung adenocarcinoma cells.
Abdulrahman N; Siveen KS; Joseph JM; Osman A; Yalcin HC; Hasan A; Uddin S; Mraiche F
J Pharm Pharmacol; 2020 Nov; 72(11):1536-1545. PubMed ID: 32667058
[TBL] [Abstract][Full Text] [Related]
5. Mucuna pruriens (L.) DC chemo sensitize human breast cancer cells via downregulation of prolactin-mediated JAK2/STAT5A signaling.
Sinha S; Sharma S; Vora J; Shah H; Srivastava A; Shrivastava N
J Ethnopharmacol; 2018 May; 217():23-35. PubMed ID: 29427634
[TBL] [Abstract][Full Text] [Related]
6. BI2536, a potent and selective inhibitor of polo-like kinase 1, in combination with cisplatin exerts synergistic effects on gastric cancer cells.
Lian G; Li L; Shi Y; Jing C; Liu J; Guo X; Zhang Q; Dai T; Ye F; Wang Y; Chen M
Int J Oncol; 2018 Mar; 52(3):804-814. PubMed ID: 29393385
[TBL] [Abstract][Full Text] [Related]
7. PD98059 impairs the cisplatin-resistance of ovarian cancer cells by suppressing ERK pathway and epithelial mesenchymal transition process.
Hou L; Hou X; Wang L; Li Z; Xin B; Chen J; Gao X; Mu H
Cancer Biomark; 2017 Dec; 21(1):187-194. PubMed ID: 29103028
[TBL] [Abstract][Full Text] [Related]
8. Tubeimoside I sensitizes cisplatin in cisplatin-resistant human ovarian cancer cells (A2780/DDP) through down-regulation of ERK and up-regulation of p38 signaling pathways.
Liu HZ; Yu C; Yang Z; He JL; Chen WJ; Yin J; Li WM; Liu HT; Wang YX
Mol Med Rep; 2011; 4(5):985-92. PubMed ID: 21687949
[TBL] [Abstract][Full Text] [Related]
9. Effects of endoplasmic reticulum stress on the autophagy, apoptosis, and chemotherapy resistance of human breast cancer cells by regulating the PI3K/AKT/mTOR signaling pathway.
Zhong JT; Yu J; Wang HJ; Shi Y; Zhao TS; He BX; Qiao B; Feng ZW
Tumour Biol; 2017 May; 39(5):1010428317697562. PubMed ID: 28459209
[TBL] [Abstract][Full Text] [Related]
10. Reactive oxygen species-mediated synergistic and preferential induction of cell death and reduction of clonogenic resistance in breast cancer cells by combined cisplatin and FK228.
Pluchino LA; Choudhary S; Wang HC
Cancer Lett; 2016 Oct; 381(1):124-32. PubMed ID: 27477899
[TBL] [Abstract][Full Text] [Related]
11. Ethacrynic acid improves the antitumor effects of irreversible epidermal growth factor receptor tyrosine kinase inhibitors in breast cancer.
Liu B; Huang X; Hu Y; Chen T; Peng B; Gao N; Jin Z; Jia T; Zhang N; Wang Z; Jin G
Oncotarget; 2016 Sep; 7(36):58038-58050. PubMed ID: 27487128
[TBL] [Abstract][Full Text] [Related]
12. Synergistic Antitumor Effects of Combined Treatment with HSP90 Inhibitor and PI3K/mTOR Dual Inhibitor in Cisplatin-Resistant Human Bladder Cancer Cells.
Kim HJ; Gong MK; Yoon CY; Kang J; Yun M; Cho NH; Rha SY; Choi YD
Yonsei Med J; 2020 Jul; 61(7):587-596. PubMed ID: 32608202
[TBL] [Abstract][Full Text] [Related]
13. The MEK1/2 Inhibitor AZD6244 Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib.
Song H; Zhang J; Ning L; Zhang H; Chen D; Jiao X; Zhang K
Med Sci Monit; 2018 May; 24():3002-3010. PubMed ID: 29737325
[TBL] [Abstract][Full Text] [Related]
14. Sildenafil potentiates the antitumor activity of cisplatin by induction of apoptosis and inhibition of proliferation and angiogenesis.
El-Naa MM; Othman M; Younes S
Drug Des Devel Ther; 2016; 10():3661-3672. PubMed ID: 27895461
[TBL] [Abstract][Full Text] [Related]
15. Effects of cisplatin on the proliferation, invasion and apoptosis of breast cancer cells following β‑catenin silencing.
Zhu X; Feng J; Fu W; Shu X; Wan X; Liu J
Int J Mol Med; 2020 Jun; 45(6):1838-1850. PubMed ID: 32186756
[TBL] [Abstract][Full Text] [Related]
16. Autophagy Inhibition Overcomes the Antagonistic Effect Between Gefitinib and Cisplatin in Epidermal Growth Factor Receptor Mutant Non--Small-Cell Lung Cancer Cells.
Liu JT; Li WC; Gao S; Wang F; Li XQ; Yu HQ; Fan LL; Wei W; Wang H; Sun GP
Clin Lung Cancer; 2015 Sep; 16(5):e55-66. PubMed ID: 25979647
[TBL] [Abstract][Full Text] [Related]
17. Novel small molecule decreases cell proliferation, migration, clone formation, and gene expression through ERK inhibition in MCF-7 and MDA-MB-231 breast cancer cell lines.
Hatzidaki E; Parsonidis P; Apostolou P; Daikopoulou V; Papasotiriou I
Anticancer Drugs; 2019 Jul; 30(6):618-627. PubMed ID: 30741723
[TBL] [Abstract][Full Text] [Related]
18. Luteolin sensitizes the antitumor effect of cisplatin in drug-resistant ovarian cancer via induction of apoptosis and inhibition of cell migration and invasion.
Wang H; Luo Y; Qiao T; Wu Z; Huang Z
J Ovarian Res; 2018 Nov; 11(1):93. PubMed ID: 30454003
[TBL] [Abstract][Full Text] [Related]
19. Computational design, chemical synthesis, and biological evaluation of a novel ERK inhibitor (BL-EI001) with apoptosis-inducing mechanisms in breast cancer.
Liu B; Fu L; Zhang C; Zhang L; Zhang Y; Ouyang L; He G; Huang J
Oncotarget; 2015 Mar; 6(9):6762-75. PubMed ID: 25742792
[TBL] [Abstract][Full Text] [Related]
20. Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.
Oliveras-Ferraros C; Vazquez-Martin A; López-Bonet E; Martín-Castillo B; Del Barco S; Brunet J; Menendez JA
Int J Oncol; 2008 Dec; 33(6):1165-76. PubMed ID: 19020749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
